About RNA-binding protein 39
RNA-binding protein 39 (RBM39) is a protein
from Homo sapiens identified by UniProt accession
Q14498, 530 residues long.
MolForge cross-references it against 0 known binders and
85 disease associations.
Target properties
| Protein name | RNA-binding protein 39 |
| UniProt accession | Q14498 |
| Gene | RBM39 |
| Organism | Homo sapiens |
| Length | 530 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (85)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.40
- endometrial cancer · score 0.21
- colorectal carcinoma · score 0.15
- intelligence · score 0.13
- waist circumference · score 0.10
- neoplasm · score 0.09
- hepatocellular carcinoma · score 0.09
- cancer · score 0.09
- mean platelet volume · score 0.08
- neuroblastoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14498-F1 | alphafold | PREDICTED | 66.79 | — |
Amino-acid sequence (530 residues)
MADDIDIEAM LEAPYKKDEN KLSSANGHEE RSKKRKKSKS RSRSHERKRS KSKERKRSRD RERKKSKSRE RKRSRSKERR RSRSRSRDRR FRGRYRSPYS GPKFNSAIRG KIGLPHSIKL SRRRSRSKSP FRKDKSPVRE PIDNLTPEER DARTVFCMQL AARIRPRDLE EFFSTVGKVR DVRMISDRNS RRSKGIAYVE FVDVSSVPLA IGLTGQRVLG VPIIVQASQA EKNRAAAMAN NLQKGSAGPM RLYVGSLHFN ITEDMLRGIF EPFGRIESIQ LMMDSETGRS KGYGFITFSD SECAKKALEQ LNGFELAGRP MKVGHVTERT DASSASSFLD SDELERTGID LGTTGRLQLM ARLAEGTGLQ IPPAAQQALQ MSGSLAFGAV AEFSFVIDLQ TRLSQQTEAS ALAAAASVQP LATQCFQLSN MFNPQTEEEV GWDTEIKDDV IEECNKHGGV IHIYVDKNSA QGNVYVKCPS IAAAIAAVNA LHGRWFAGKM ITAAYVPLPT YHNLFPDSMT ATQLLVPSRR
Explore RNA-binding protein 39 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets